IVBXF — Innovent Biologics Inc/ADR
—
OTC ·
Unknown ·
Unknown ·
CIK 1774163 ·
Last close
$12.80
Market Cap
$22.32B
52W High
$15.01
52W Low
$9.10
ADV30
1,422
Next earnings
2026-08-25
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 37,347,839,000 | 17,344,705,000 | 17,991,596,000 |
| Jun 2025 | — | — | — | — | 23,594,272,000 | 9,540,139,000 | 9,172,452,000 |
| Dec 2024 | — | — | — | — | 21,602,602,000 | 7,508,185,000 | 8,484,873,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-15,092,803,000
Inventory
$1,301,745,000
Receivables
—
ST Investments
$886,741,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$15,706,229,760
EBITDA
$1,702,771,968
Free Cash Flow
$3,228,137,984
Enterprise Value
$2,618,083,584
Total Cash
$20,002,985,984
Total Debt
$2,323,205,888
Shares Out
1,743,864,650
Trailing EPS
$0.07
Book Value
$1.79
ROE
7.0%
ROA
2.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 13,041,523,000 | 2,140,913,000 | 813,565,000 | 37,347,839,000 | 17,991,596,000 | 19,356,243,000 | 10,001,012,000 |
| Dec 2024 | 9,421,888,000 | 258,119,000 | -94,631,000 | 21,602,602,000 | 8,484,873,000 | 13,117,729,000 | 1,287,024,000 |
| Dec 2023 | 6,206,070,000 | -909,210,000 | -1,027,913,000 | 20,627,360,000 | 8,099,779,000 | 12,527,581,000 | 147,810,000 |
| Dec 2022 | 4,556,380,000 | -2,581,885,000 | -2,179,270,000 | 17,588,845,000 | 6,858,896,000 | 10,729,949,000 | -1,918,804,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VLTO | Veralto Corp | $23.08B | $94.68 | — |
| TPL | Texas Pacific Land Corp | $23.46B | $340.19 | — |
| TPR | TAPESTRY, INC. | $23.55B | $118.12 | — |
| SDMHF | Sartorius Stedim Biotech S.A./ADR | $23.74B | $244.00 | — |
| AMCCF | Amcor plc | $20.43B | $44.18 | — |
News headlines (Yahoo Finance, 1h cache)
Top China Biopharma Stocks to Watch, According to Bernstein
2026-09-30 06:18 · Yahoo
Innovent Biologics (SEHK:1801) Stock Still Looks Below Fair Value As Shares Rose 153%
2026-09-29 23:10 · Yahoo
2026 IMS Oral Presentation: Innovent Announces Updated Phase 1 Clinical Data of Trispecific Antibody IBI3003 (GPRC5D/BCMA/CD3) in Patients with Relapsed or Refractory Multiple Myeloma
2026-09-29 07:45 · Yahoo
Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy
2026-09-28 10:30 · Yahoo
Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squ
2026-09-28 00:00 · Yahoo
Lilly’s latest China drug deal; Immunovant’s setback in lupus
2026-09-24 14:14 · Yahoo
Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting
2026-09-23 08:48 · Yahoo
Altruist Biologics' Suzhou Site Receives EMA GMP Certification, Enabling Product Commercialization for the European Market
2026-09-22 14:00 · Yahoo
Altruist Biologics Congratulates Partner LongBio Pharma on the BLA Acceptance of LP-003 by the China NMPA
2026-09-14 13:00 · Yahoo
OPKO Health (OPK) Cashes In A Future Royalty Stream Early
2026-09-14 03:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.